Moreover, the PI3K/Akt pathway is crucial for sustaining CML, as inhibiting PI3K signaling effectively disrupts BCR-ABL1-driven oncogenic processes, leading to the elimination of early-stage CML cells [75]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.